Fras JP, Davies MJ, Rosenstock J, Prez Manghi FC, Fernndez Land L, Bergman BK, et al
The SCALE program also included two RCT conducted in patients with T2D on background oral anti-diabetes medications with 21,22 /without 22 insulin, aiming to assess the efficacy of liraglutide 3.0 mg on weight loss at 56 weeks
In the pre-specified 104-week extension, participants on 12 mg reached an average of -30.3% (-85.0 lbs / -38.5 kg) , with no weight-loss plateau observed
Peaka GLP-1 is a dietary supplement, not an FDA-approved medication
You should not combine GLP-1 tablets with other GLP-1 medicines unless your prescriber has specifically advised you to do so
We are building a continuous data layer that connects therapy with real-world patient insights enabling better decisions for clinicians and more meaningful evidence for pharmaceutical partners, he further adds